BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________ FORM 10-Q _____________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-39696 ___________________________ ...

EXHIBIT 99.1 Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment is progressing well in COMPANION-002, a Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Enrollment is expected to be complet ...

CTX-009 抗体 - Compass Therapeutics, Inc. 宣布其 bispecific DLL4/VEGF-A 抗体 CTX-009 获得 FDA 快速通道认定[1] - CTX-009 与紫杉醇联合治疗在晚期胆道癌患者中显示出有希望的临床反应[2] - CTX-009 是一种同时阻断 Delta-like ligand 4 (DLL4) 和 vascular endothelial growth factor A (VEGF-A) 信号通路的双特异性抗体[3] 胆道癌患者情况 - 美国每年约有 23,000 例胆道癌患者，其中只有 10% 的患者处于早期阶段，大多数患者处于局部晚期或转移性胆道癌阶段[4] FDA 快速通道认定 - FDA 快速通道认定旨在帮助药物更快地到达患者，加快具有填补医疗需求潜力的药物的开发和审查[5] Compass Therapeutics 公司 - Compass Therapeutics 是一家致力于肿瘤治疗的临床阶段生物制药公司，专注于血管生成、免疫系统和肿瘤生长之间的关系[6]

BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on CTX-009, the Company's bispecific DLL4/VEGF-A antibody, at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference to be held at the Salt Palace Convention Center in Salt Lake City, Utah from April 17–19, 2024. Presentation Details: P ...

Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental recognition of the tumor by CD8+ T-Cells, which drive the adaptive immune attack on the tumor. Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471. This combination was surprisingly synergistic. The proposed mechanism for this effect suggests the involvement of NK-cells, whi ...

Today we will be looking at three penny stocks with the power to 10x your $1K investment. The three firms discussed below have outsized potential to turn a small capital allocation into a much larger return.Two of the three firms discussed below have very strong catalysts on their side. The other operates in the biotech sector which is notoriously volatile. Regardless, all three have a lot of untapped potential. Penny stocks are no different than any others from the perspective that good businesses create g ...

公司财务状况 - 公司自成立以来累计亏损3.15亿美元[125] - 预计未来几年内将继续承担重大支出和运营亏损[126] - 预计未来几年内也可能无法盈利[127] - 预计将需要大量资金来实现业务目标[129] - 预计现有资金将支持运营费用和资本支出至2026年中期[130] 临床试验风险 - 公司的业务发展依赖于临床试验并最终商业化[134] - 临床开发是漫长且昂贵的过程，结果不确定[137] - 临床试验可能会因多种因素而被暂停或终止[140] - 临床试验结果可能不足以获得监管批准[144] - 临床试验的中期和初步结果可能会随着更多患者数据的出现而发生变化[145] 市场监管批准风险 - FDA等监管机构对产品候选人的审批过程长期且不可预测[159] - 产品候选人可能无法获得批准的原因多种多样[160] - 申请市场监管批准需要提供足够证据[162] - FDA对新产品的审批能力可能受多种因素影响[166] - 任何产品候选者的市场监管批准可能受限制和条件[171] 市场推广风险 - 公司产品获得市场认可可能面临挑战[175] - 未来发生的不良事件可能导致更严格的监管和潜在的审批延迟[176] - 产品候选人的市场机会可能受限[179] - 建立营销、销售和分销能力存在风险[183] - 产品责任诉讼可能限制产品商业化[186] 知识产权风险 - 公司无法获得和维持产品候选人的专利保护可能影响竞争力[198] - 知识产权保护依赖于遵守各种程序、文件提交、费用支付等要求[202] - 知识产权诉讼可能对公司产生重大不利影响[205] - 公司依赖专利保护和保密协议来保护无法专利化的专有技术[206] - 公司可能会成为专利和其他知识产权诉讼的一方[208] 公司经营风险 - 公司可能依赖第三方合作伙伴进行产品候选者的发现、开发和商业化[221] - 公司竞争对手可能比我们更快地获得监管批准[225] - 我们需要扩大组织规模，但可能会遇到困难[226] - 我们高度依赖关键人员[227] - 如果我们未能保持适当和有效的财务报告内部控制，可能会影响我们准确和及时地制作财务报表的能力[228] 法律合规风险 - 公司受到反腐败、反洗钱、出口管制、制裁等法律监管[236] - 公司与政府机构的交易受到监管[237] - 公司未能遵守环境、健康和安全法律法规可能面临罚款或处罚[238] - 公司将继续因为成为上市公司而产生增加的成本[240] - 公司是一家新兴成长型公司和较小的报告公司，无法确定减少报告要求是否会影响投资者[241]

Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line data from this study are expected by the end of 2024.Enrollment in COMPANION-003, the Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC) was completed in the first quarter of 2024; top-line data from Stage 1 of this study are expected by mid-year 2024. Initiated planning of a Phase 2 monot ...

文章核心观点 - 公司开发的生物特异性检查点抑制剂CTX-8371具有独特的作用机制,可以同时靶向PD-1和PD-L1,并诱导细胞表面PD-1的蛋白水解性切割和丢失 [1][2] - CTX-8371相比已上市的抗PD-1和抗PD-L1疗法在体外和体内实验中表现出更强的抗肿瘤活性 [2][3] - CTX-8371与公司的CD137激动性抗体CTX-471的组合在小鼠肿瘤模型中进一步增强了抗肿瘤疗效 [3] 公司概况 - 公司是一家临床阶段的肿瘤生物制药公司,专注于开发自主研发的抗体类治疗药物 [3] - 公司的科学重点是探讨血管生成、免疫系统和肿瘤生长之间的关系 [3] - 公司的产品管线针对多个关键生物通路,包括通过针对血管生成的靶向药物调节微血管,通过激活肿瘤微环境中的效应细胞诱导强大的免疫反应,以及缓解肿瘤逃逸免疫监视的免疫抑制机制 [3] - 公司计划根据临床和非临床数据,将产品候选药物作为单独疗法或与公司管线中的抗体组合用药推进临床开发 [3] 临床进展 - 公司的生物特异性抗体CTX-8371的IND申请已于2023年底获得FDA批准,预计将在本季度内给首例患者给药 [3]